WO2022228424A1 - Protéine de fusion bifonctionnelle anti-egfr/vegf et son utilisation - Google Patents

Protéine de fusion bifonctionnelle anti-egfr/vegf et son utilisation Download PDF

Info

Publication number
WO2022228424A1
WO2022228424A1 PCT/CN2022/089244 CN2022089244W WO2022228424A1 WO 2022228424 A1 WO2022228424 A1 WO 2022228424A1 CN 2022089244 W CN2022089244 W CN 2022089244W WO 2022228424 A1 WO2022228424 A1 WO 2022228424A1
Authority
WO
WIPO (PCT)
Prior art keywords
egfr
fusion protein
vegf
seq
acid sequence
Prior art date
Application number
PCT/CN2022/089244
Other languages
English (en)
Chinese (zh)
Inventor
邓岚
黄浩旻
朱祯平
Original Assignee
丹生医药技术(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丹生医药技术(上海)有限公司 filed Critical 丹生医药技术(上海)有限公司
Priority to CN202280030685.7A priority Critical patent/CN117242097A/zh
Publication of WO2022228424A1 publication Critical patent/WO2022228424A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La présente invention relève du domaine technique des protéines de fusion, en particulier une protéine de fusion bifonctionnelle anti-EGFR/VEGF et son utilisation. La protéine de fusion bifonctionnelle anti-EGFR/VEGF comprend : (a) Un anticorps anti-EGFR ou un fragment de liaison à l'antigène de celui-ci, et (b) le domaine D2 de la région extracellulaire de VEGFR1. La protéine de fusion selon la présente invention a de grandes perspectives d'application clinique dans le traitement de maladies liées à une expression élevée ou anormale de l'EGFR et du VEGF.
PCT/CN2022/089244 2021-04-27 2022-04-26 Protéine de fusion bifonctionnelle anti-egfr/vegf et son utilisation WO2022228424A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280030685.7A CN117242097A (zh) 2021-04-27 2022-04-26 一种抗egfr/vegf双功能融合蛋白及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110458717.0 2021-04-27
CN202110458717.0A CN115246886A (zh) 2021-04-27 2021-04-27 一种抗egfr/vegf双功能融合蛋白及其用途

Publications (1)

Publication Number Publication Date
WO2022228424A1 true WO2022228424A1 (fr) 2022-11-03

Family

ID=83695778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/089244 WO2022228424A1 (fr) 2021-04-27 2022-04-26 Protéine de fusion bifonctionnelle anti-egfr/vegf et son utilisation

Country Status (3)

Country Link
CN (2) CN115246886A (fr)
TW (1) TW202300530A (fr)
WO (1) WO2022228424A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633883A (zh) * 2012-02-24 2012-08-15 上海白泽生物科技有限公司 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
CN109563166A (zh) * 2016-04-28 2019-04-02 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
CN110835375A (zh) * 2018-08-16 2020-02-25 上海洛启生物医药技术有限公司 一种抗pd-1/egfr双特异性抗体及其用途
CN112552410A (zh) * 2019-09-26 2021-03-26 三生国健药业（上海）股份有限公司 一种抗体融合蛋白及其制法和在抗肿瘤中的应用
CN113004391A (zh) * 2017-08-16 2021-06-22 蜻蜓疗法股份有限公司 结合nkg2d、cd16和egfr、ccr4或pd-l1的蛋白质

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633883A (zh) * 2012-02-24 2012-08-15 上海白泽生物科技有限公司 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
CN109563166A (zh) * 2016-04-28 2019-04-02 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
CN113004391A (zh) * 2017-08-16 2021-06-22 蜻蜓疗法股份有限公司 结合nkg2d、cd16和egfr、ccr4或pd-l1的蛋白质
CN110835375A (zh) * 2018-08-16 2020-02-25 上海洛启生物医药技术有限公司 一种抗pd-1/egfr双特异性抗体及其用途
CN112552410A (zh) * 2019-09-26 2021-03-26 三生国健药业（上海）股份有限公司 一种抗体融合蛋白及其制法和在抗肿瘤中的应用

Also Published As

Publication number Publication date
CN115246886A (zh) 2022-10-28
TW202300530A (zh) 2023-01-01
CN117242097A (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
WO2020043184A1 (fr) Anticorps bifonctionnel anti-pd-1 et anti-vegfa, composition pharmaceutique et utilisation associées
WO2021042694A1 (fr) Anticorps à domaine unique anti-vegf et son utilisation
WO2021219127A1 (fr) Anticorps bispécifique ciblant her2 et pd-1 et son utilisation
EP4209513A1 (fr) Anticorps bispécifique anti-vegf-anti-pd-l1, composition pharmaceutique de celui-ci et utilisations associées
WO2021155635A1 (fr) Anticorps bispécifique anti-cd3 et anti-cd123 et son utilisation
US20220010008A1 (en) Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
WO2021170082A1 (fr) Anticorps anti-cd47/anti-pd-l1 et ses utilisations
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
CN110922486A (zh) 一种分离的结合抗原psma的蛋白及其用途
KR20210063782A (ko) c-kit에 대한 항체 및 이의 용도
IL304095A (en) Mesothelin binding molecule and its application
WO2019192493A1 (fr) Anticorps monoclonal anti-lag-3 humain et son utilisation
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
WO2021244554A1 (fr) Anticorps bispécifique anti-pdl1 × egfr
WO2022068894A1 (fr) Molécule bifonctionnelle ciblant simultanément pd-l1 et vegf et son utilisation médicale
CN113354737B (zh) 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
WO2021244371A1 (fr) Protéine de fusion anti-pd-l1/vegf
WO2022228424A1 (fr) Protéine de fusion bifonctionnelle anti-egfr/vegf et son utilisation
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
TW202146446A (zh) 一種抗pd-l1和egfr的四價雙特異性抗體
CN110563847A (zh) 用于治疗性用途的免疫检查点抑制剂
CN111840571B (zh) 一种抗体药物偶联物及其用途
WO2021244587A1 (fr) Protéine de fusion anti-pd-l1/tgf-ss
WO2023020592A1 (fr) PROTÉINE DE FUSION D'ANTICORPS BIFONCTIONNEL TGF-β/VEGF
WO2023041065A1 (fr) Anticorps ciblant ceacam5/6 humain, procédé de préparation et application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22794894

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22794894

Country of ref document: EP

Kind code of ref document: A1